Business Description
Kyverna Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US5019761049
Description
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 34.1 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.23 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 39.11 | |||||
9-Day RSI | 33.06 | |||||
14-Day RSI | 32.92 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 17.17 | |||||
Quick Ratio | 17.17 | |||||
Cash Ratio | 16.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -101.11 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -120.62 | |||||
ROA % | -25.48 | |||||
ROIC % | -237.68 | |||||
ROC (Joel Greenblatt) % | -411.83 | |||||
ROCE % | -28.41 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.96 | |||||
Price-to-Tangible-Book | 0.96 | |||||
EV-to-EBIT | 0.47 | |||||
EV-to-EBITDA | 0.48 | |||||
EV-to-FCF | 0.49 | |||||
Price-to-Net-Current-Asset-Value | 1 | |||||
Price-to-Net-Cash | 1.02 | |||||
Earnings Yield (Greenblatt) % | 212.77 | |||||
FCF Yield % | -12.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KYTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kyverna Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -1.626 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 32.92 | ||
14-Day ATR ($) | 1.330407 | ||
20-Day SMA ($) | 10.4065 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 6.75 - 35.06 | ||
Shares Outstanding (Mil) | 43.12 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Kyverna Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Kyverna Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Kyverna Therapeutics Inc Frequently Asked Questions
What is Kyverna Therapeutics Inc(KYTX)'s stock price today?
The current price of KYTX is $8.05. The 52 week high of KYTX is $35.06 and 52 week low is $6.75.
When is next earnings date of Kyverna Therapeutics Inc(KYTX)?
The next earnings date of Kyverna Therapeutics Inc(KYTX) is 2024-08-30 Est..
Does Kyverna Therapeutics Inc(KYTX) pay dividends? If so, how much?
Kyverna Therapeutics Inc(KYTX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |